Inflammatory bowel disease, colitis, and cancer: unmasking the chronic inflammation link.

IF 2.5 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

International Journal of Colorectal Disease Pub Date : 2024-10-28 DOI:10.1007/s00384-024-04748-y

Vahid Khaze Shahgoli, Saeed Noorolyai, Mahya Ahmadpour Youshanlui, Hossein Saeidi, Hadi Nasiri, Behzad Mansoori, Uffe Holmskov, Behzad Baradaran

{"title":"Inflammatory bowel disease, colitis, and cancer: unmasking the chronic inflammation link.","authors":"Vahid Khaze Shahgoli, Saeed Noorolyai, Mahya Ahmadpour Youshanlui, Hossein Saeidi, Hadi Nasiri, Behzad Mansoori, Uffe Holmskov, Behzad Baradaran","doi":"10.1007/s00384-024-04748-y","DOIUrl":null,"url":null,"abstract":"Background: Chronic inflammation is a significant driver in the development of various diseases, including cancer. Colitis-associated colorectal cancer (CA-CRC) refers to the increased risk of colorectal cancer in individuals with chronic inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease.Methods: This narrative review examines the link between chronic inflammation and CA-CRC. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science, focusing on studies published between 2000 and 2024. Studies were selected based on relevance to the role of inflammation in CA-CRC, specifically targeting molecular pathways and clinical implications. Both clinical and mechanistic studies were reviewed.Conclusion: Sustained inflammation in the colon fosters a pro-tumorigenic environment, leading to the initiation and progression of CA-CRC. Prevention strategies must focus on controlling chronic inflammation, optimizing IBD management, and implementing regular screenings. Emerging therapies targeting key inflammatory pathways and immune responses, along with microbiome modulation, hold promise for reducing CA-CRC risk. Understanding these molecular mechanisms provides a path toward personalized treatment and better outcomes for patients with IBD at risk of colorectal cancer.","PeriodicalId":13789,"journal":{"name":"International Journal of Colorectal Disease","volume":"39 1","pages":"173"},"PeriodicalIF":2.5000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11513726/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Colorectal Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00384-024-04748-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Chronic inflammation is a significant driver in the development of various diseases, including cancer. Colitis-associated colorectal cancer (CA-CRC) refers to the increased risk of colorectal cancer in individuals with chronic inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease.

Methods: This narrative review examines the link between chronic inflammation and CA-CRC. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science, focusing on studies published between 2000 and 2024. Studies were selected based on relevance to the role of inflammation in CA-CRC, specifically targeting molecular pathways and clinical implications. Both clinical and mechanistic studies were reviewed.

Conclusion: Sustained inflammation in the colon fosters a pro-tumorigenic environment, leading to the initiation and progression of CA-CRC. Prevention strategies must focus on controlling chronic inflammation, optimizing IBD management, and implementing regular screenings. Emerging therapies targeting key inflammatory pathways and immune responses, along with microbiome modulation, hold promise for reducing CA-CRC risk. Understanding these molecular mechanisms provides a path toward personalized treatment and better outcomes for patients with IBD at risk of colorectal cancer.

查看原文本刊更多论文

炎症性肠病、结肠炎和癌症：揭开慢性炎症的联系。

背景：慢性炎症是包括癌症在内的各种疾病的重要诱因。结肠炎相关性结直肠癌（CA-CRC）是指溃疡性结肠炎和克罗恩病等慢性炎症性肠病（IBD）患者罹患结直肠癌的风险增加：这篇叙述性综述探讨了慢性炎症与 CA-CRC 之间的联系。我们使用 PubMed、Scopus 和 Web of Science 进行了全面的文献检索，重点关注 2000 年至 2024 年间发表的研究。选择研究的依据是炎症在 CA-CRC 中的作用，特别是针对分子途径和临床影响。对临床和机理研究都进行了综述：结肠中的持续炎症会形成有利于肿瘤的环境，导致 CA-CRC 的发生和发展。预防策略必须侧重于控制慢性炎症、优化 IBD 管理和实施定期筛查。针对关键炎症通路和免疫反应的新兴疗法以及微生物组调节有望降低 CA-CRC 风险。了解这些分子机制将为有结肠直肠癌风险的 IBD 患者提供个性化治疗和更好的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Colorectal Disease 医学-外科

CiteScore

4.90

自引率

3.60%

发文量

206

审稿时长

3-8 weeks

期刊介绍： The International Journal of Colorectal Disease, Clinical and Molecular Gastroenterology and Surgery aims to publish novel and state-of-the-art papers which deal with the physiology and pathophysiology of diseases involving the entire gastrointestinal tract. In addition to original research articles, the following categories will be included: reviews (usually commissioned but may also be submitted), case reports, letters to the editor, and protocols on clinical studies. The journal offers its readers an interdisciplinary forum for clinical science and molecular research related to gastrointestinal disease.